Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Clinical Research Institute of Michigan, LLC
mi
from
Chesterfield, MI
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Clinical Research Institute of Michigan, LLC
mi
from
Chesterfield, MI
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Center for Digestive & Liver Disease, Inc.
mi
from
Mexico, MO
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Center for Digestive & Liver Disease, Inc.
mi
from
Mexico, MO
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Remington Davis Inc.
mi
from
Columbus, OH
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Remington Davis Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Oklahoma Foundation for Digestive Research
mi
from
Oklahoma City, OK
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Oklahoma Foundation for Digestive Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Nashville Medical Research Institute
mi
from
Nashville, TN
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Nashville Medical Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients
Determination of Intestinal Permeability and Response to Treatment in Patients With Eosinophilic Esophagitis
Status: Enrolling
Updated:  9/26/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients
Determination of Intestinal Permeability and Response to Treatment in Patients With Eosinophilic Esophagitis
Status: Enrolling
Updated: 9/26/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated:  10/10/2013
GSK Investigational Site
mi
from
Lakewood, CO
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated: 10/10/2013
GSK Investigational Site
mi
from
Lakewood, CO
Click here to add this to my saved trials
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated:  10/10/2013
GSK Investigational Site
mi
from
Orlando, FL
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated: 10/10/2013
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated:  10/10/2013
GSK Investigational Site
mi
from
Minneapolis, MN
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated: 10/10/2013
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated:  10/10/2013
GSK Investigational Site
mi
from
Knoxville, TN
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)
Status: Enrolling
Updated: 10/10/2013
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy
Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study
Status: Enrolling
Updated:  10/18/2013
Massachusetts General Hospital
mi
from
Boston, MA
Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy
Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study
Status: Enrolling
Updated: 10/18/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy
Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study
Status: Enrolling
Updated:  10/18/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy
Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study
Status: Enrolling
Updated: 10/18/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy
Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study
Status: Enrolling
Updated:  10/18/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy
Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study
Status: Enrolling
Updated: 10/18/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
Nemours Children's Clinic
mi
from
Jacksonville, FL
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
Nemour's Children's Clinic
mi
from
Pensacola, FL
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
Nemour's Children's Clinic
mi
from
Pensacola, FL
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
University of Iowa
mi
from
Iowa City, IA
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
Via Cristi Hospitals Wichita, Inc.
mi
from
Wichita, KA
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
Via Cristi Hospitals Wichita, Inc.
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
Dayton Children's
mi
from
Dayton, OH
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
Dayton Children's
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated:  10/22/2013
West Virginia University Research Corporation
mi
from
Morgantown, WV
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Status: Enrolling
Updated: 10/22/2013
West Virginia University Research Corporation
mi
from
Morgantown, WV
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Birmingham, AL
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
San Diego, CA
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Denver, CO
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Newark, DE
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Evanston, IL
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
New Orleans, LA
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Ayer, MA
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Ayer, MA
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Duluth, MN
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Duluth, MN
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Teaneck, NJ
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Bronx, NY
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Asheville, NC
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated:  10/25/2013
Clinical Research Facility
mi
from
Beloit, WI
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Status: Enrolling
Updated: 10/25/2013
Clinical Research Facility
mi
from
Beloit, WI
Click here to add this to my saved trials
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Status: Enrolling
Updated:  10/25/2013
Massachusetts General Hospital
mi
from
Boston, MA
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Status: Enrolling
Updated: 10/25/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Gralise® for Chronic Pelvic Pain
Efficacy of Gralise® for Chronic Pelvic Pain
Status: Enrolling
Updated:  10/29/2013
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Efficacy of Gralise® for Chronic Pelvic Pain
Efficacy of Gralise® for Chronic Pelvic Pain
Status: Enrolling
Updated: 10/29/2013
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Aurora, CO
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Washington,
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Chicago, IL
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Chicago, IL
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Louisville, KY
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Baltimore, MD
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Morristown, NJ
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Stony Brook, NY
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Cleveland, OH
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Pittsburgh, PA
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials